Biden鈥檚 July Executive Order Includes Drug Pricing Provisions. But Will They Do Enough?
The July 9 directive addresses the importation of prescription drugs and broader efforts to reduce the high cost of medicines.
Drug Costs
221-240 of 705 results
-
-
KHN鈥檚 鈥榃hat the Health?鈥: Here Comes Reconciliation
Democrats in Congress reached a tentative agreement to press ahead on a partisan bill that would dramatically expand health benefits for people on Medicare, those who buy their own insurance and individuals who have been shut out of coverage in states that didn鈥檛 expand Medicaid. Meanwhile, controversy continues to rage over whether vaccinated Americans will need a booster to protect against covid-19 variants, and who will pay for a new drug to treat Alzheimer鈥檚 disease. Rachel Cohrs of Stat and Sarah Karlin-Smith of the Pink Sheet join KHN鈥檚 Julie Rovner to discuss these issues and more. Also, Rovner interviews KHN鈥檚 Rae Ellen Bichell, who reported and wrote the latest KHN-NPR 鈥淏ill of the Month鈥 episode about a mother and daughter who fought an enormous emergency room bill.
-
As Congress Wrestles With Plans to Expand Medicare, Becerra Says Any One Will Do
In an interview for KHN鈥檚 鈥淲hat the Health?鈥 podcast, HHS Secretary Xavier Becerra says the administration is eager for Congress to make changes to Medicare that will provide more benefits and make more older adults eligible for the program. He also said a priority will be making permanent the enhanced premium subsidies for Affordable Care Act marketplace plans.
By Julie Rovner -
KHN鈥檚 鈥榃hat the Health?鈥: Becerra Urges Congress to Expand Medicare, Address Rx Prices
Health and Human Services Secretary Xavier Becerra is the special guest for this bonus episode of KHN鈥檚 鈥淲hat the Health?鈥 podcast. He and host Julie Rovner discuss a breadth of topics the secretary oversees, including covid-19, prescription drug prices, Medicare, Medicaid and the Affordable Care Act.
-
Paying Billions for Controversial Alzheimer鈥檚 Drug? How About Funding This Instead?
Aduhelm, approved by the Food and Drug Administration last month despite questions about its efficacy, could be prescribed to at least 1 million patients a year, for a price tag of about $56 billion. Experts suggest there might be better ways to spend that money.
-
How One Rural Town Without a Pharmacy Is Crowdsourcing to Get Meds
As more independently owned community pharmacies close, a Colorado town is crowdsourcing ways of getting prescription medicines delivered to those who can鈥檛 travel the long distance to the closest pharmacy. But even those stopgap measures don鈥檛 always work.
-
States Step Up Push to Regulate Pharmacy Drug Brokers
In an ongoing effort to control prescription drug costs, states are targeting the companies that mediate deals among drug manufacturers, health insurers and pharmacies. The pharmacy benefit managers say they negotiate lower prices for patients, yet the nitty-gritty occurs largely behind a curtain that lawmakers are trying to pull back.
-
KHN鈥檚 鈥榃hat the Health?鈥: How to Expand Health Coverage
Democrats in Congress and the states are devising strategies to expand health coverage 鈥 through the Affordable Care Act, Medicare, Medicaid and a 鈥減ublic option.鈥 But progress remains halting, at best. Meanwhile, lawmakers in Washington may have to agree on how to control prescription drug prices if they wish to finance their coverage initiatives. Alice Miranda Ollstein of Politico, Tami Luhby of CNN and Shefali Luthra of The 19th join KHN鈥檚 Julie Rovner to discuss these issues and more. Also, Rovner interviews Michelle Andrews, who reported and wrote last month鈥檚 KHN-NPR 鈥淏ill of the Month鈥 episode about a very expensive sleep study.
-
KHN鈥檚 鈥榃hat the Health?鈥: Our 200th Episode!
The federal approval of a controversial drug to treat Alzheimer鈥檚 disease has reignited the debate over drug prices and the way the Food and Drug Administration makes decisions. Meanwhile, President Joe Biden seeks to gain goodwill overseas as he announces the U.S. will provide 500 million doses of covid vaccine to international health efforts. Sarah Karlin-Smith of the Pink Sheet, Margot Sanger-Katz of The New York Times and Joanne Kenen of Politico join KHN鈥檚 Julie Rovner to discuss these issues and more. Also, Rovner interviews Chiquita Brooks-LaSure, the new administrator of the Centers for Medicare & Medicaid Services. And to mark the podcast鈥檚 200th episode, the panelists discuss what has surprised them most and least over the past four years.
-
Change to Gilead Assistance Program Threatens PrEP Access, HIV Advocates Say
Safety-net clinics especially are bracing for how the drugmaker鈥檚 policy shift could reduce their budgets and hamstring their ability to provide care to an at-risk population.
-
FDA Weighs Approval of a Lucrative Alzheimer鈥檚 Drug, but Benefits Are Iffy
The agency is to decide by June 7 whether to greenlight Biogen鈥檚 drug aducanumab, despite a near-unanimous rejection of the product by an FDA advisory committee of outside experts in November. Some scientists at the agency have endorsed the drug, though.
By Harris Meyer -
KHN鈥檚 鈥榃hat the Health?鈥: The Drug Price Dilemma
Republicans, Democrats and the public at large agree that prices for prescription drugs are too high. But no one seems to know how to fix it. Vanderbilt University drug price researcher Stacie Dusetzina explains the basics of why drugs cost so much and why it鈥檚 hard to do something about it. Joanne Kenen of Politico, Sarah Karlin-Smith of the Pink Sheet and Anna Edney of Bloomberg News join KHN鈥檚 Julie Rovner to discuss the prospects for policy changes.
-
KHN Journalist Combs for Clues on Covid’s Origins
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here鈥檚 a collection of their appearances.
-
Biden Administration Signals It鈥檚 in No Rush to Allow Canadian Drug Imports
Federal officials asked a court to dismiss a suit by drugmakers over the policy enacted by the Trump administration that would allow states to bring in cheaper prescription medications from Canada. The filing said the lawsuit was moot because it鈥檚 unclear when or if the FDA would approve any state鈥檚 importation plan.
-
Colorado Lawmakers Wage Multifront Assault on High Drug Costs
Colorado is one of many states resolved not to wait for federal action to reduce drug costs. Its legislature is considering several ways to lower costs for consumers and the state.
-
KHN鈥檚 鈥榃hat the Health?鈥: Drug Price Effort Hits a Snag
Democratic leaders in Congress have vowed to pass legislation to address high prescription drug prices this year, but some moderates in their own party appear to be balking. Meanwhile, younger teens are now eligible for a covid-19 vaccine and the Biden administration reinstated anti-discrimination policy for LGBTQ people in health care. Joanne Kenen of Politico, Sarah Karlin-Smith of the Pink Sheet and Rachel Cohrs of Stat join KHN鈥檚 Julie Rovner to discuss these issues and more.
-
Democrats Disagree About How to Spend Potential Prescription Drug Windfall
After a year of uncharacteristically being on the same page when it comes to health care, Democratic lawmakers are at loggerheads about what to do next. Most agree the time is ripe to tackle high drug prices. But they divide over whether to take savings from that to move to a 鈥楳edicare for All鈥 insurance system, enhance the current Medicare program or strengthen benefits under the Affordable Care Act.
By Julie Rovner -
KHN鈥檚 鈥榃hat the Health?鈥: 100 Days of Health Policy
It鈥檚 100 days into Joe Biden鈥檚 presidency and a surprisingly large number of health policies have been announced. But health is notably absent from the administration鈥檚 $1.8 trillion spending plan for American families, making it unclear how much more will get done this year. Meanwhile, the Centers for Disease Control and Prevention loosens its mask-wearing recommendations for those who have been vaccinated, but the new rules are confusing. Joanne Kenen of Politico, Mary Ellen McIntire of CQ Roll Call and Sarah Karlin-Smith of the Pink Sheet join KHN鈥檚 Julie Rovner to discuss these issues and more. Plus, Rovner interviews KHN鈥檚 Julie Appleby, who reported the latest KHN-NPR 鈥淏ill of the Month鈥 episode.
-
FDA Seeks a New Way to Review Old Drugs Without Causing Prices to Soar
A misguided federal program called the Unapproved Drugs Initiative, which put the FDA鈥檚 stamp of approval on old drugs, led to higher prices. It鈥檚 scrapped. So now what?
By Harris Meyer -
KHN鈥檚 鈥榃hat the Health?鈥: Planning for Round Two
The ink is barely dry on the recent covid relief bill, but Democrats in Congress and President Joe Biden are wasting no time gearing up for their next big legislative package. Meanwhile, predictions of more states expanding Medicaid have proved premature. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat and Kimberly Leonard of Business Insider join KHN鈥檚 Julie Rovner to discuss these issues and more. Plus, Rovner interviews KHN鈥檚 Lauren Weber, who reported the latest KHN-NPR 鈥淏ill of the Month鈥 episode.